(Q37937044)

25 August 2017

1 reference

title

Targeted molecular therapy in peripheral T-cell lymphomas (English)

1 reference

25 August 2017

1 reference

ChEBI release 2020-05-28

3

Pier Luigi Zinzani

1 reference

25 August 2017

4

Stefano A Pileri

1 reference

25 August 2017

Fernando Roncolato

1

1 reference

25 August 2017

Anna Gazzola

series ordinal

2

1 reference

25 August 2017

Pier Paolo Piccaluga

series ordinal

5

1 reference

25 August 2017

publication date

1 October 2011

1 reference

Expert Review of Hematology

25 August 2017

published in

1 reference

25 August 2017

volume

4

1 reference

25 August 2017

issue

5

1 reference

25 August 2017

page(s)

551-562

1 reference

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

25 August 2017

cites work

1 reference

Prognostic markers in peripheral T-cell lymphoma

21 January 2018

1 reference

Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score

21 January 2018

1 reference

Novel agents in development for peripheral T-cell lymphoma

21 January 2018

1 reference

Anaplastic lymphoma kinase: signalling in development and disease

21 January 2018

1 reference

Anaplastic lymphoma kinase in human cancer

21 January 2018

1 reference

Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target

21 January 2018

1 reference

Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms

21 January 2018

1 reference

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies.

21 January 2018

1 reference

Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets

21 January 2018

1 reference

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

Cyr61 promotes breast tumorigenesis and cancer progression

21 January 2018

1 reference

Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation

21 January 2018

1 reference

High resolution SNP array genomic profiling of peripheral T cell lymphomas, not otherwise specified, identifies a subgroup with chromosomal aberrations affecting the REL locus.

21 January 2018

1 reference

Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type

21 January 2018

1 reference

Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.

21 January 2018

1 reference

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma

21 January 2018

1 reference

MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation

21 January 2018

1 reference

Mechanisms of proteasome inhibitor action and resistance in cancer

21 January 2018

1 reference

Development of the proteasome inhibitor Velcade (Bortezomib).

21 January 2018

1 reference

Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.

21 January 2018

1 reference

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

21 January 2018

1 reference

Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis

21 January 2018

1 reference

Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.

21 January 2018

1 reference

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma

21 January 2018

1 reference

Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease

21 January 2018

1 reference

Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab

21 January 2018

1 reference

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

21 January 2018

1 reference

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

21 January 2018

1 reference

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

21 January 2018

1 reference

Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.

21 January 2018

1 reference

Expression of CD52 in peripheral T-cell lymphoma

21 January 2018

1 reference

CD52 expression in non-mycotic T- and NK/T-cell lymphomas

21 January 2018

1 reference

Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy

21 January 2018

1 reference

CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies

21 January 2018

1 reference

Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia

21 January 2018

1 reference

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.

21 January 2018

1 reference

Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.

21 January 2018

1 reference

The language of covalent histone modifications

21 January 2018

1 reference

Histone acetyltransferases

21 January 2018

1 reference

The human histone deacetylase family

21 January 2018

1 reference

The Sir2 family of protein deacetylases

21 January 2018

1 reference

Histone deacetylase inhibitors in lymphoma

21 January 2018

1 reference

Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression

21 January 2018

1 reference

Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation

21 January 2018

1 reference

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 January 2018

1 reference

Genetic dissection of histone deacetylase requirement in tumor cells

21 January 2018

1 reference

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

21 January 2018

1 reference

Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy

21 January 2018

1 reference

HSP90 and the chaperoning of cancer

21 January 2018

1 reference

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action

21 January 2018

1 reference

The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells

21 January 2018

1 reference

Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma.

21 January 2018

1 reference

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

21 January 2018

1 reference

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma

21 January 2018

1 reference

Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports

21 January 2018

1 reference

Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide

21 January 2018

1 reference

Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation

21 January 2018

1 reference

The IL-2/IL-2 receptor system: a current overview

21 January 2018

1 reference

Exploiting the mammalian target of rapamycin pathway in hematologic malignancies

21 January 2018

1 reference

Inhibition of mammalian target of rapamycin signaling by everolimus induces senescence in adult T-cell leukemia/lymphoma and apoptosis in peripheral T-cell lymphomas.

21 January 2018

1 reference

Targeted therapy in lymphoma

21 January 2018

1 reference

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma

21 January 2018

1 reference

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

21 January 2018

1 reference

Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary

21 January 2018

1 reference

Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies

21 January 2018

1 reference

Peripheral T-cell lymphoma classification: the matter of cellular derivation.

21 January 2018

1 reference

Differential expression of NF-κB pathway genes among peripheral T-cell lymphomas

21 January 2018

1 reference

Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EHM.11.55

1 reference

25 August 2017

1 reference